Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
TEL AVIV, Israel & PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new positive efficacy, safety and tolerability results for Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia. In the…
Press Release: Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia - Newscast
Tue, 11 Mar 2025 10:07:00 GMT Teva Pharmaceutical Industries Limited ( NYSE: TEVA) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:00 AM ET Good morning, everyone. My name is Balaji Prasad. I'm the Senior ...
Thu, 06 Mar 2025 15:59:00 GMT 2025--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the supplemental New ...
Mon, 24 Feb 2025 02:23:19 GMT Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human immunoglobulin G 1(IgG1)-λ2 monoclonal antibody, duvakitug, in treating moderate-to ...
Sun, 23 Feb 2025 16:00:00 GMT TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd ... presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of ...
Sat, 22 Feb 2025 23:41:00 GMT Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug ... market-moving breaking financial news. Try Now>> See the ...
